Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer

Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer

(2019) Young-Bae Kim et al.   INTERNATIONAL JOURNAL OF CANCER

HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer.

(2019) Takeshi Fukumoto et al.   CANCER RESEARCH

Prognostic role of ARID1A negative expression in gastric cancer

(2019) Mai Ashizawa et al.   Scientific Reports

KRT17 as a prognostic biomarker for stage II colorectal cancer

(2019) Daisuke Ujiie et al.   CARCINOGENESIS

ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion

(2019) Mike R. Wilson et al.   Nature Communications

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

(2018) Seung Tae Kim et al.   NATURE MEDICINE

Repurposing Pan-HDAC Inhibitors for ARID1A -Mutated Ovarian Cancer

(2018) Takeshi Fukumoto et al.   Cell Reports

EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions

(2018) Sho Sasaki et al.   Gastric Cancer

Estimation of lifetime cumulative incidence and mortality risk of gastric cancer

(2017) Yukari Taniyama et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

ARID1A-mutated ovarian cancers depend on HDAC6 activity

(2017) Benjamin G. Bitler et al.   NATURE CELL BIOLOGY

PARP inhibitors: Synthetic lethality in the clinic

(2017) Christopher J. Lord et al.   SCIENCE

The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells

(2017) Tianfu Yu et al.   Oncotarget

Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer

(2016) Julie George et al.   CLINICAL CANCER RESEARCH

Targeting EZH2 in cancer

(2016) Kimberly H Kim et al.   NATURE MEDICINE

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A

(2016) Chris T. Williamson et al.   Nature Communications

SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2

(2015) Kimberly H Kim et al.   NATURE MEDICINE

Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers

(2015) Benjamin G Bitler et al.   NATURE MEDICINE

Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations

(2015) Hiroyuki Abe et al.   PATHOBIOLOGY

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

(2015) J. Shen et al.   Cancer Discovery

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

ARID1B is a specific vulnerability in ARID1A-mutant cancers

(2014) Katherine C Helming et al.   NATURE MEDICINE

OpenCFU, a New Free and Open-Source Software to Count Cell Colonies and Other Circular Objects

(2013) Quentin Geissmann   PLoS One

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

(2012) Michael T. McCabe et al.   NATURE

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells

(2012) Sarah K Knutson et al.   Nature Chemical Biology

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation

(2012) W. Qi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ARID1A Mutations in Cancer: Another Epigenetic Tumor Suppressor?

(2012) Jennifer N. Wu et al.   Cancer Discovery

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer

(2011) Kai Wang et al.   NATURE GENETICS